← Filings of STE

Tables in the 10-Q of STERIS plc

58 tables with numbers, filed Nov 5, 2026. Each one downloads as a CSV for Excel or Google Sheets, with the filing's address in the last row. Only the layout is tidied (a "$" or ")" in a cell of its own is joined to its number); no value is changed. Open the filing on sec.gov ↗

Ireland		98-1455064
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
70 Sir John Rogerson's Quay,	Dublin 2,	Ireland	D02 R296
(Address of principal executive offices)		(Zip code)

Title of each class	Trading symbol(s)	Name of Exchange on Which Registered
Ordinary Shares, $0.001 par value	STE	New York Stock Exchange
2.700% Senior Notes due 2031	STE/31	New York Stock Exchange
3.750% Senior Notes due 2051	STE/51	New York Stock Exchange

		Page
Part I—Financial Information
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	30
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	45
Item 4.	Controls and Procedures	45
Part II—Other Information
Item 1.	Legal Proceedings	46

	September 30, 2026	March 31, 2026
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$531.1		$439.6
Accounts receivable (net of allowances of $31.8 and $27.3 respectively)	1,005.2		1,092.8
Inventories, net	737.0		631.8
Prepaid expenses and other current assets	205.9		230.4

	Three Months Ended September 30,	Six Months Ended September 30,
	2026	2025		2026	2025
Revenues:
Product	$816.9		$745.4		$1,554.1	$1,435.9
Service	771.7		714.9		1,527.3	1,415.4
Total revenues	1,588.6		1,460.3		3,081.3	2,851.4
Cost of revenues:
Product	410.0		390.8		778.4	750.5

	Three Months Ended September 30, 2026
	Ordinary Shares	Retained Earnings	Accumulated Other Comprehensive Loss	Non-controlling Interest	Total Equity
	Number	Amount
Balance at June 30, 2026	97.5		$4,179.5		$3,154.5	$(127.3)	$14.5	$7,221.3
Comprehensive income:
Net income	—		—		213.7	—	0.4	214.1
Other comprehensive loss	—		—		—	(22.0)	—	(22.0)
Repurchases of ordinary shares	(0.4)		(100.4)		—	—	—	(100.4)

	Six Months Ended September 30, 2026
	Ordinary Shares	Retained Earnings	Accumulated Other Comprehensive Loss	Non-controlling Interest	Total Equity
	Number	Amount
Balance at March 31, 2026	97.8		$4,280.9		$3,015.9	$(113.1)	$13.6	$7,197.2
Comprehensive income:
Net income	—		—		413.8	—	1.3	415.1
Other comprehensive loss	—		—		—	(36.2)	—	(36.2)
Repurchases of ordinary shares	(1.0)		(215.9)		—	—	—	(215.9)

	Three Months Ended September 30, 2025
	Ordinary Shares	Retained Earnings	Accumulated Other Comprehensive Loss	Non-controlling Interest	Total Equity
	Number	Amount
Balance at June 30, 2025	98.4		$4,431.0		$2,596.5	$(70.5)	$12.9	$6,969.9
Comprehensive income:
Net income	—		—		191.9	—	0.6	192.5
Other comprehensive loss	—		—		—	(5.6)	—	(5.6)
Repurchases of ordinary shares	(0.4)		(101.0)		—	—	—	(101.0)

	Six Months Ended September 30, 2025
	Ordinary Shares	Retained Earnings	Accumulated Other Comprehensive Loss	Non-controlling Interest	Total Equity
	Number	Amount
Balance at March 31, 2025	98.3		$4,420.4		$2,475.3	$(292.3)	$12.4	$6,615.8
Comprehensive income:
Net income	—		—		369.2	—	1.3	370.4
Other comprehensive income	—		—		—	216.2	—	216.2
Repurchases of ordinary shares	(0.5)		(111.6)		—	—	—	(111.6)

Standard	Date of Issuance	Description	Date of Adoption	Effect on the financial statements or other significant matters
Standards that have been adopted in fiscal 2027
ASU 2025-05 "Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses for Accounts Receivable and Contract Assets."	July 2025	The standard introduces a practical expedient allowing entities to assume current economic conditions, as of the balance sheet date, remain unchanged when estimating expected credit losses for current trade receivables and contract assets. The guidance is effective for fiscal years beginning after December 15, 2025, including interim periods.	First Quarter Fiscal 2027	We adopted this standard in fiscal 2027 with no material impact to the consolidated financial statements.
Standards that have not yet been adopted
ASU 2024-03"Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses."	November 2024	The standard provides guidance to enhance disclosures related to the disaggregation of income statement expenses. The standard requires, in the notes to the financial statements, disclosure of specified information about certain costs and expenses which includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each relevant expense caption. The standard also requires amounts that are already required to be disclosed under U.S. GAAP in the same disclosure as the other disaggregation requirements, disclosure of a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, and disclosure of the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this standard are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027.	NA	We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements.

	Six Months Ended September 30,
	2026	2025
Operating activities:
Net income	$415.1		$370.4
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, depletion, and amortization	249.4		241.1
Deferred income taxes	(0.1)		(0.1)
Share-based compensation expense	34.5		33.1

(in millions)	Three Months Ended September 30,	Six Months Ended September 30,
Restructuring plans	2026	2025	2026	2025
Severance and other compensation related costs	$4.8		$1.6		$4.8	$3.3
Lease and other contract termination and other costs	—		0.2		—	0.2
Product rationalization charges (credits)(1)	6.3		(1.0)		6.3	(1.0)
Accelerated depreciation and amortization	0.1		0.3		0.1	0.4
Asset impairment charges	14.2		—		14.2	—
Restructuring charges, net	$25.5		$1.2		$25.5	$2.9

(in millions)	September 30, 2026	March 31, 2026
Raw materials	$253.9		$225.4
Work in process	95.0		90.7
Finished goods	427.1		355.2
Reserve for excess and obsolete inventory	(39.1)		(39.4)
Inventories, net	$737.0		$631.8

(in millions)	September 30, 2026	March 31, 2026
Land and land improvements (1)	$112.6		$112.3
Buildings and leasehold improvements	961.1		903.6
Machinery and equipment	1,503.0		1,434.3
Information systems	330.0		316.3
Radioisotope	861.9		829.9
Construction in progress (1)	472.6		509.5
Total property, plant, and equipment	4,241.2		4,105.9

ASU 2025-06 "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40) Targeted Improvements to the Accounting for Internal-Use Software	September 2025	The standard removes all references to prescriptive and sequential software development stages and requires entities to begin capitalizing software costs when management has both authorized and committed to funding the software project, and it is probable that the project will both be completed and the software will be used to perform the function intended. Capitalized internal-use software costs are now subject to the same disclosure requirements as property, plant, and equipment (PPE), even if they are presented as intangible assets or under a different line item. The amendments in this standard are effective for annual periods beginning after December 15, 2027 and interim reporting periods within those annual reporting periods, with early adoption permitted.	NA	We are in the process of evaluating the impact that the standard update will have on our consolidated financial statements.
ASU 2025-10 "Government Grants (Topic 832) Accounting for Government Grants Received by Business Entities"	December 2025	The standard provides authoritative guidance on the recognition, measurement, presentation, and disclosure of government grants received by business entities. The standard defines a government grant as a transfer of a monetary or tangible nonmonetary asset from a government to a business entity in a nonexchange transaction and requires a grant to be recognized only when it is probable that the entity will comply with the grant’s conditions and that the grant will be received. The amendments introduce an accounting model largely based on International Accounting Standard (IAS) 20, under which grants related to assets or income are recognized over the periods in which the related costs or expenses are incurred. The standard also amends Topic 832, which previously included only disclosure requirements, and provides guidance on presentation and repayment of grants. The guidance excludes certain transactions such as income tax items, below-market interest rate loans, and government guarantees from its scope. The amendments are effective for annual periods beginning after December 15, 2028 (including interim periods within those annual periods) for public business entities and one year later for all other entities. Early adoption is permitted.	NA	We are in the process of evaluating the impact that the standard update will have on our consolidated financial statements.

Three Months Ended September 30, 2026
(in millions)	Healthcare	AST		Life Sciences	Corporate	Company
Revenues	$1,122.4		$295.6		$170.6		$—	$1,588.6
Segment expenses
Cost of revenues	650.0		148.6		75.4
Selling, general, and administrative	175.2		14.2		17.0
Research and development	28.1		0.7		2.5
Total income from operations before adjustments	$269.2		$132.1		$75.8		$(86.7)	$390.5

	Three Months Ended September 30,	Six Months Ended September 30,
(shares in millions)	2026	2025		2026	2025
Weighted average shares outstanding—basic	97.3		98.4		97.5	98.4
Dilutive effect of share equivalents	0.3		0.5		0.3	0.5
Weighted average shares outstanding and share equivalents—diluted	97.6		98.8		97.7	98.8

	Fiscal 2027	Fiscal 2026
Risk-free interest rate	4.03%		4.03%
Expected life of options	6.1 years	6.1 years
Expected dividend yield of stock	1.11%		1.11%
Expected volatility of stock	28.65%		28.16%

	Number of Options	Weighted Average Exercise Price Per Share		Average Remaining Contractual Term	Aggregate Intrinsic Value (in millions)
Outstanding at March 31, 2026	1,716,867		$204.51
Granted	221,967		231.00
Exercised	(54,828)		113.00
Forfeited	(3,023)		228.73
Outstanding at September 30, 2026	1,880,983		$210.37		5.8 years	$35.4
Exercisable at September 30, 2026	1,376,796		$198.27		4.7 years	$35.4

	Number of Restricted Shares	Number of Restricted Share Units		Weighted Average Grant Date Fair Value
Non-vested at March 31, 2026	456,080		30,289		$226.73
Granted	211,047		19,316		210.73
Vested	(205,231)		(19,699)		217.94
Forfeited	(10,359)		(807)		225.06
Non-vested at September 30, 2026	451,537		29,099		$223.20

(in millions)	Warranties
Balance at March 31, 2026	$17.5
Warranties issued during the period	6.2
Settlements made during the period	(9.0)
Balance at September 30, 2026	$14.7

					Fair Value Measurements
(in millions)		Carrying Value		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
			Level 1		Level 2		Level 3
September 30,	March 31,		September 30,	March 31,		September 30,	March 31,		September 30,	March 31,
Assets:
Cash and cash equivalents		$531.1	$439.6				$531.1		$439.6		$—	$—	$—	$—
Forward and swap contracts (1)		0.8	0.2				—		—		0.8	0.2	—	—
Deferred compensation plans (2)		1.5	1.3				1.5		1.3		—	—	—	—

(in millions)	Defined Benefit Plans (1)	Foreign Currency Translation		Total Accumulated Other Comprehensive Loss
	Three Months	Six Months		Three Months	Six Months	Three Months		Six Months
Beginning Balance	$(1.1)		$(1.1)		$(126.2)		$(112.0)		$(127.3)	$(113.1)
Other Comprehensive Income (Loss) before reclassifications	0.2		0.4		(22.1)		(36.2)		(21.9)	(35.8)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	(0.2)		(0.3)		—		—		(0.2)	(0.3)
Net current-period Other Comprehensive Income (Loss)	—		0.1		(22.1)		(36.2)		(22.0)	(36.2)
Balance at September 30, 2026	$(1.1)		$(1.1)		$(148.2)		$(148.2)		$(149.3)	$(149.3)

	Three Months Ended September 30,
(dollars in millions)	2026	2025		Change	Percent Change
Total revenues	$1,588.6		$1,460.3		$128.3	8.8%
Revenues by type:
Service revenues	771.7		714.9		56.8	8.0%
Consumable revenues	496.3		452.0		44.3	9.8%
Capital equipment revenues	320.6		293.5		27.1	9.2%
Revenues by geography:

Tables in the 10-Q of STERIS plc

Table 1 after “(Exact name of registrant as specified in its charter)”

Table 2 after “SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:”

Table 3 after “Index”

Table 4 after “(in millions, except par value)”

Table 5 after “(Unaudited)”

Table 6 after “(Unaudited)”

Table 7 after “(Unaudited)”

Table 8 after “(Unaudited)”

Table 9 after “(Unaudited)”

Table 10 after “(Unaudited)”

Table 11 after “(Unaudited)”

Table 12 after “Recently Issued Accounting Standards impacting the Company are presented in the following table:”

Table 13 after “For the Three and Six Months Ended September 30, 2026 and 2025”

Table 14 after “The following table summarizes our total pre-tax restructuring expenses recorded during the three and six months ended September 30, 2026 an”

Table 15 after “The following table summarizes our restructuring liability balances:”

Table 16 after “. Inventories, net consisted of the following:”

Table 17 after “Information related to the major categories of our depreciable assets is as follows:”

Table 18 after “Indebtedness was as follows:”

Table 19 after “Additional information related to our Consolidated Balance Sheets is as follows:”

Table 20 after “September 30, 2026 and 2025:”

Table 21 after “September 30, 2026 and 2025:”

Table 22 after “For the Three and Six Months Ended September 30, 2026 and 2025”

Table 23 after “For the Three and Six Months Ended September 30, 2026 and 2025”

Table 24 after “Individual facilities, equipment, and intellectual properties are utilized by both the Healthcare and Life Sciences segments at varying leve”

Table 25 after “Individual facilities, equipment, and intellectual properties are utilized by both the Healthcare and Life Sciences segments at varying leve”

Table 26 after “Financial information for each of our United States and international geographic areas is presented in the following table. Revenues are att”

Table 27 after “Financial information for each of our United States and international geographic areas is presented in the following table. Revenues are att”

Table 28 after “For the Three and Six Months Ended September 30, 2026 and 2025”

Table 29 after “We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share ”

Table 30 after “Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because ”

Table 31 after “The following weighted average assumptions were used for options granted during the first six months of fiscal 2027 and 2026:”

Table 32 after “A summary of share option activity is as follows:”

Table 33 after “For the Three and Six Months Ended September 30, 2026 and 2025”

Table 34 after “Changes in our warranty liability during the first six months of fiscal 2027 were as follows:”

Table 35 after “The following table shows the fair value of our financial assets and liabilities at September 30, 2026 and March 31, 2026:”

Table 36 after “Accumulated other comprehensive loss shown in our Consolidated Statements of Shareholders' Equity and changes in our balances, net of tax, f”

Table 37 after “Accumulated other comprehensive loss shown in our Consolidated Statements of Shareholders' Equity and changes in our balances, net of tax, f”

Table 38 after “The following table summarizes the calculation of our free cash flow for the six months ended September 30, 2026 and 2025:”

Table 39 after “The following tables compare our revenues for the three and six months ended September 30, 2026 to the revenues for the three and six months”

Table 40 after “Revenues from other foreign locations increased 8.5% to $388.2 million for the three months ended September 30, 2026, as compared to $357.8 ”

Table 41 after “Our gross profit is affected by the volume, pricing, and mix of sales of our products and services, as well as the costs associated with the”

Table 42 after “second quarter of fiscal 2026 of 44.2%. Favorable impacts from pricing (130 basis points), tariff refunds (130 basis points) and mix (10 bas”

Table 43 after “The following table compares our operating expenses for the three and six months ended September 30, 2026 to the three and six months ended ”

Table 44 after “The following table compares our operating expenses for the three and six months ended September 30, 2026 to the three and six months ended ”

Table 45 after “The following table summarizes our total pre-tax restructuring expenses recorded during the three and six months ended September 30, 2026 an”

Table 46 after “Liabilities related to restructuring activities are recorded as current liabilities in the accompanying Consolidated Balance Sheets within "”

Table 47 after “Non-operating expenses, net consists of interest expense on debt, offset by interest earned on cash, cash equivalents, short-term investment”

Table 48 after “Non-operating expenses, net consists of interest expense on debt, offset by interest earned on cash, cash equivalents, short-term investment”

Table 49 after “The following tables compare our tax expense and effective income tax rates for the three and six months ended September 30, 2026 and 2025:”

Table 50 after “The following tables compare our tax expense and effective income tax rates for the three and six months ended September 30, 2026 and 2025:”

Table 51 after “The following tables compare business segment revenues as well as impacts from acquisitions, divestitures, and foreign currency movements fo”

Table 52 after “The following tables compare business segment revenues as well as impacts from acquisitions, divestitures, and foreign currency movements fo”

Table 53 after “The following table compares business segment and Corporate operating income for the three and six months ended September 30, 2026 and 2025.”

Table 54 after “The following table summarizes significant components of our cash flows for the six months ended September 30, 2026 and 2025:”

Table 55 after “The following tables present summarized results of operations for the six months ended September 30, 2026 and summarized balance sheet infor”

Table 56 after “The following tables present summarized results of operations for the six months ended September 30, 2026 and summarized balance sheet infor”

Table 57 after “The following table summarizes the ordinary shares repurchase activity during the second quarter of fiscal 2027 under our ordinary share rep”

Table 58 after “Exhibits required by Item 601 of Regulation S-K”

	Three Months Ended September 30, (unaudited)
	As reported, U.S. GAAP	Impact of Acquisitions		Impact of Divestitures	Impact of Foreign Currency Movements	U.S. GAAP Growth		Organic Growth	Constant Currency Organic Growth
(dollars in millions)	2026	2025		2026	2025	2026		2026	2026	2026
Segment revenues:
Healthcare	$1,122.4		$1,033.8		$11.3		$—		$0.6		8.6%	7.5%	7.4%
AST	295.6		281.5		—		—		(1.0)		5.0%	5.0%	5.3%
Life Sciences	170.6		145.0		—		—		(0.7)		17.7%	17.7%	18.1%
Total	$1,588.6		$1,460.3		$11.3		$—		$(1.1)		8.8%	8.0%	8.1%

	Six Months Ended September 30, (unaudited)
	As reported, U.S. GAAP	Impact of Acquisitions		Impact of Divestitures	Impact of Foreign Currency Movements	U.S. GAAP Growth		Organic Growth	Constant Currency Organic Growth
(dollars in millions)	2026	2025		2026	2025	2026		2026	2026	2026
Segment revenues:
Healthcare	$2,170.8		$2,008.5		$18.1		$—		$4.8		8.1%	7.2%	6.9%
AST	593.2		562.7		—		—		2.2		5.4%	5.4%	5.0%
Life Sciences	317.4		280.2		—		—		0.3		13.3%	13.3%	13.2%
Total	$3,081.3		$2,851.4		$18.1		$—		$7.3		8.1%	7.4%	7.2%

Summarized Results of Operations
(in millions)	Six Months Ended
	September 30, 2026
Revenues	$1,711.3
Gross profit	946.0
Operating costs arising from transactions with non-issuers and non-guarantors, net	329.3
Income from operations	476.9
Non-operating income arising from transactions with subsidiaries that are non-issuers and non-guarantors, net	722.8

Summarized Balance Sheet Information
(in millions)
	September 30, 2026	March 31, 2026
Receivables due from non-issuers and non-guarantor subsidiaries	$22,462.2		$21,513.5
Other current assets	1,034.5		1,039.2
Total current assets	$23,496.7		$22,552.7
Non-current receivables due from non-issuers and non-guarantor subsidiaries	$1,280.3		$1,280.3
Goodwill	298.9		298.0

(in millions, except per share data)	Total Number ofShares Purchased	Average Price PaidPer Share		Total Number ofShares Purchased asPart of PubliclyAnnounced Plans		Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans at Period End
July 1-31	—		$—			—	$900.0
August 1-31	0.4		235.46			0.4	805.8
September 1-30	—		230.21			—	800.0
Total	0.4	(1)	$235.14		(1)	0.4	$800.0

ExhibitNumber	Exhibit Description
3.1	STERIS plc Amended Memorandum and Articles of Association (filed as Exhibit 3.1 to STERIS plc Form 10-K for the fiscal year ended March 31, 2019 (Commission File No. 001-38848), and incorporated herein by reference).
10.1	Description of STERIS plc Non-Employee Director Compensation Program.*
22.1	List of Guarantor Subsidiaries with respect to the 2.700% Notes due 2031 and 3.750% Notes due 2051 issued by STERIS Irish FinCo Unlimited Company (filed as Exhibit 22.1 to Form 10-K for the fiscal year ended March 31, 2021 (Commission File No. 001-38848), and incorporated by reference).
31.1	Certification of the Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a).
31.2	Certification of the Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a).
32.1	Certification of the Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.SCH	Inline Schema Document.